Key Points
- Director Christobel Selecky sold 25,000 shares on Jan. 20 at an average price of $7.51 for a total of $187,750, and had previously sold 50,000 shares on Jan. 16 at $5.00 for $250,000.
- ImmunityBio shares were up 6.8% (opened at $6.92) with a 12‑month range of $1.83–$7.98; the company has a market cap of about $6.82 billion and a negative P/E ratio.
- Positive regulatory news—an FDA Type B meeting and plans to resubmit an sBLA for ANKTIVA within 30 days—has driven the rally, while analyst views are mixed but average to a "Moderate Buy" with a consensus target near $12.00.
ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Christobel Selecky sold 25,000 shares of the business's stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Christobel Selecky also recently made the following trade(s):
- On Friday, January 16th, Christobel Selecky sold 50,000 shares of ImmunityBio stock. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00.
ImmunityBio Stock Up 6.8%
Shares of ImmunityBio stock opened at $6.92 on Thursday. ImmunityBio, Inc. has a twelve month low of $1.83 and a twelve month high of $7.98. The business has a 50-day moving average price of $2.54 and a 200-day moving average price of $2.52. The firm has a market cap of $6.82 billion, a price-to-earnings ratio of -16.88 and a beta of 0.03.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to the consensus estimate of $31.88 million. On average, equities analysts expect that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.
Wall Street Analyst Weigh In
IBRX has been the subject of a number of recent research reports. Weiss Ratings reissued a "sell (e+)" rating on shares of ImmunityBio in a report on Monday, December 29th. Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the company an "overweight" rating in a research report on Tuesday. D. Boral Capital reissued a "buy" rating and issued a $24.00 price objective on shares of ImmunityBio in a research note on Tuesday. Finally, Jefferies Financial Group upped their target price on shares of ImmunityBio from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Friday, December 12th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $12.00.
View Our Latest Research Report on IBRX
Institutional Investors Weigh In On ImmunityBio
Institutional investors have recently made changes to their positions in the company. Courier Capital LLC increased its position in ImmunityBio by 12.5% during the 2nd quarter. Courier Capital LLC now owns 45,000 shares of the company's stock valued at $119,000 after purchasing an additional 5,000 shares during the period. Bell & Brown Wealth Advisors LLC lifted its position in shares of ImmunityBio by 6.4% in the 3rd quarter. Bell & Brown Wealth Advisors LLC now owns 82,750 shares of the company's stock worth $204,000 after purchasing an additional 5,000 shares during the period. Creative Planning boosted its stake in shares of ImmunityBio by 9.2% during the second quarter. Creative Planning now owns 62,028 shares of the company's stock valued at $164,000 after purchasing an additional 5,231 shares in the last quarter. Blair William & Co. IL increased its holdings in ImmunityBio by 2.7% during the second quarter. Blair William & Co. IL now owns 239,814 shares of the company's stock valued at $633,000 after buying an additional 6,314 shares during the period. Finally, Cetera Investment Advisers raised its stake in ImmunityBio by 56.9% in the second quarter. Cetera Investment Advisers now owns 18,551 shares of the company's stock worth $49,000 after buying an additional 6,731 shares in the last quarter. Institutional investors own 8.58% of the company's stock.
Trending Headlines about ImmunityBio
Here are the key news stories impacting ImmunityBio this week:
- Positive Sentiment: FDA discussions gave ImmunityBio a clear path to resubmit an sBLA for ANKTIVA in papillary non‑muscle invasive bladder cancer, and the company plans to submit additional information within 30 days — a direct catalyst for upside. ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
- Positive Sentiment: Company press release confirmed a Type B End‑of‑Phase meeting with the FDA and outlined next steps for ANKTIVA’s sBLA, reinforcing the regulatory-path narrative that investors are rewarding. ImmunityBio Advances Regulatory Discussions with FDA
- Positive Sentiment: HC Wainwright raised its long‑term outlook (FY2030 EPS estimate to $0.68), signaling growing analyst optimism about ImmunityBio’s future earnings power (consensus had been negative).
- Positive Sentiment: At least one independent shop reaffirmed a “buy” and a high price target ($24), which may support further speculative buying interest. Benzinga
- Neutral Sentiment: The stock’s rally has extended over multiple sessions (reported as a 12‑day run in some outlets), driven in part by momentum trading and heavy volume rather than fresh clinical data. ImmunityBio (IBRX) rockets on 12th day, hits fresh high
- Neutral Sentiment: Market coverage notes short‑sellers are under pressure as the rapid share surge forces potential covering — a technical factor that can amplify volatility but isn’t a fundamental guarantee of sustained gains. Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses
- Neutral Sentiment: Multiple outlets covered the FDA meeting and ensuing price moves; much of the market reaction reflects expectations about the timing and sufficiency of the planned resubmission analyses. ImmunityBio stock soars after FDA meeting on bladder cancer treatment
- Negative Sentiment: Some analysts and commentary warn of momentum risks — advising traders to be cautious or to trim exposure amid a speculative rally and the possibility that regulatory requests could require more data or time than investors expect. Top 3 Health Care Stocks You May Want To Dump In January
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.
Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
